Standout Papers

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, ... 2008 2026 2014 2020 509
  1. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 (2008)
    Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research

Citation Impact

1 by Nobel laureates 13 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Cancer therapy with antibodies
2024 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
2 intermediate papers

Works of Grant Wickman being referenced

Abstract 1005: The bispecific antibody zanidatamab's (ZW25's) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
2021
Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers
2017

Author Peers

Author Molecular Biology Oncology RNMI PRM Last Decade Papers Cites
Grant Wickman 755 368 89 286 21 1.3k
Howard Mellett 45 642
J. Savat 2 6 281
J. David Dean 10 199
Matti Romo 432 89 196 114 39 3.8k
Yuri Rosenberg 62 2 5 15 512

All Works

Loading papers...

Rankless by CCL
2026